Clinical Trial

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Completed Phase 1
View on ClinicalTrials.gov →
Summary
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-06
notable Primary completion moved earlier: 2026-09-15 -> 2026-07-22 2026-08-06
minor Completion moved earlier: 2026-09-15 -> 2026-07-22 2026-08-06
Trial Details
NCT Number NCT05800873
Lead Sponsor Everest Medicines (China) Co.,Ltd.
Conditions Primary Membranous Nephropathy
Enrollment 31 participants
Start Date 2023-05-15
Primary Completion 2026-07-22 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-05